Skip to main content

Advertisement

SpringerLink
Log in

Adjuvante hormonelle Therapie beim Mammakarzinom

Adjuvant endocrine therapy in breast cancer

  • Themenschwerpunkt: Therapiekonzepte Beim Operablen Mammakarzinom
  • Published:
Acta Chirurgica Austriaca Aims and scope Submit manuscript

Zusammenfassung

In der vorliegenden Arbeit soll eine Übersicht gegeben werden über die adjuvante hormonelle Behandlung des primären Mammakarzinoms. Referiert werden Studien zur prophylaktischen Kastration (sowohl strahlentherapeutisch wie operativ) und zur adjuvanten Tamoxifen-Therapie. Rational eingesetzt, ist die adjuvante hormonelle Therapie des primären Mammakarzinoms eine wirkungsvolle Behandlung sowohl zur Verlängerung des rezidivfreien intervalls als auch zu einer Reduktion der Mortalität.

Summary

This paper gives a survey of adjuvant endocrine treatment in primary breast cancer. Studies of either surgical or radiation castration as well as adjuvant tamoxifen therapy are reviewed. The rational use of adjuvant endocrine treatment in early breast cancer delays recurrences and reduces mortality effectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Adair FE, Treves N, Farrow JH, Schamagel IM: Clinical effects of surgical and x-ray castration in mammary cancer; JAMA 1945;128:161–167.

    Google Scholar 

  2. Anonymus: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet 1985;1:836–839.

  3. Anonymus: Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at eight years by Nolvadex Adjuvant Trial Organisation. Br J Cancer 1988;57:608–611.

  4. Beatson GT: On the treatment of inoperable cases of breast carcinoma: suggestion for a new method of treatment, with illustrative cases. Lancet 1896;2:104.

    Article  Google Scholar 

  5. Boccardo F, Rubagotti A, Bruzzi P, Cappellini M, Isola G, Nenci I, Pifanelli A, Scanni A, Sismondi P, Santi L, Genta F, Saccani F, Sassi M, Malacame P, Donati D, Farris A, Castagnetta L, DiCarlo A, Traina A, Galletto L, Smerieri F, Buzzi F: Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: Results of a multicentric Italian study. J Clin Oncol 1990;8: 1310–1320.

    PubMed  CAS  Google Scholar 

  6. Bonadonna G, Valagussa P: Adjuvant chemoendocrine therapy in breast cancer. J Clin Oncol 1986;4:451–454.

    PubMed  CAS  Google Scholar 

  7. Breast Cancer Trials Committee, Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet 1987;2:171–175.

    Google Scholar 

  8. Brusterhaltende Therapie beim Mammakarzinom-Indikationen und Konsequenzen. Ergebnisse einer multidisziplinären Konsensus Tagung. Mitt Ditsch Krebsges 1990;2:6–9.

  9. Bryant AJS, Weir JA: Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet 1981;153:660–664.

    PubMed  CAS  Google Scholar 

  10. Cole MP: Prophylactie compared with therapeutic x-ray artificial menopause, in Joslin CAF. Gleave EN (eds). The clinical management of advanced breast cancer, 2nd Tenovus Workshop. Cardiff. Alpha Omega Alpha Publishing. 1970. pp 2–11.

    Google Scholar 

  11. Cole MP: A clinical trial of an artificial menopause in carcinoma of the breast, in Namer M, Lalanne CM (eds). Hormones and breast cancer, 55. Paris, INSERM, 1975, pp. 143–150.

    Google Scholar 

  12. Cole MP, Jones CTA, Todd IDH: A new anti-oestrogenic agent in late breast cancer and early clinical appraisal of ICI 46,474. Br J Cancer 1971;25:270–275.

    PubMed  CAS  Google Scholar 

  13. Consensus Development Conference Report: Adjuvant chemotherapy for breast cancer. JAMA 1985;254:3461–3463.

    Google Scholar 

  14. Coombes RC, Chilvers C, Dowsett M, Gazet J-C, Ford HT, Bettelheim R, Gordon C, Smith IE, Zava D, Powles TJ: Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. Cancer Res 1982;42(suppl):3415s-3419s.

    PubMed  CAS  Google Scholar 

  15. Cummings FJ, Gray R, Davis TE, Tormey DC, Harris JE, Falkson G, Arseneau J: Adjuvant Tamoxifen Treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo. Ann Intern Med 1985;103:324–329.

    PubMed  CAS  Google Scholar 

  16. Early Breast Cancer Trialists Collaborative Group: Treatment of early breast cancer, Vol. 1, Worldwide evidence 1985–1990. Oxford, Oxford University Press, 1990.

    Google Scholar 

  17. Fisher B, Brown A, Wolmark N, Redmont C, Wickerham DL, Wittliff, J, Dimitrov, N, Legault-Poisson S, Schipper H, Prager D: Prolongin tamoxifen theapy for primary breast cancer. Ann Intern Med 1987;106:649–654.

    PubMed  CAS  Google Scholar 

  18. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479–484.

    Article  PubMed  CAS  Google Scholar 

  19. Fisher B, Redmont C, Brown A, Fisher ER, Wolmark N, Bowman D, Plotkin D, Wolter J, Bornstein R, Legault-Poisson S, Saffer EA: Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project trial. J Clin Oncol 1986;4:459–471.

    PubMed  CAS  Google Scholar 

  20. Fisher B, Redmond C, Dimitrov NV, Bowman D, Legault-Poisson S, Wickerham DL, Wolmark N, Fisher ER, Margolese R, Sutherland C, Glass A, Foster R, Caplan R: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors N Engl J Med 1989;320:473–478.

    Article  PubMed  CAS  Google Scholar 

  21. Fomander T, Rutquist LE, Cedemark B, Glas U, Mattson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar M-L: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989:1:117–119.

    Article  Google Scholar 

  22. Goldhirsch, A, Gelber RD: Adjuvant chemoendocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig studies III and IV, in Senn HJ, Goldhirsch, A, Gelber RD, Osterwalder B (eds). Adjuvant Therapy of Primary Breast Cancer (Recent Results in Cancer Research). Berlin-Heidelberg-New York. Springer. 1989, pp 153–162.

    Google Scholar 

  23. Horsley JS: Bilateral oophorectomy with radical operation for cancer of the breast. Surgery 1944;15:590–601.

    Google Scholar 

  24. Hubay CA, Gordon NH, Pearson OH, Marshall JS, McGuire WL: Eight-year follow-up of adjuvant therapy for stage II breast cancer. World J Surgery 1985;9:738–749.

    Article  CAS  Google Scholar 

  25. Jensen EV, DeSombre ER, Jungblut PW: Estrogen receptors in hormone-responsive tissues and tumors, in Wissler RW, Dao TL, Wood S (eds): Endogenous factors influencing host-tumor balance. Chicago, University of Chicago Press, 1967, pp 15–30.

    Google Scholar 

  26. Jonat W, Kaufmann M, Abel U: Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG trial 1), in Senn HJ, Goldhirsch, A, Gelber RD, Osterwalder B (eds). Adjuvant Therapy of Primary Breast Cancer (Recent Results in Cancer Research), Berlin-Heidelberg-New York, Springer, 1989, pp 163–169.

    Google Scholar 

  27. Jordan VC: Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications. Breast Cancer Res Treat 1983:3 (Suppl 1):73–86.

    Article  CAS  Google Scholar 

  28. Kaufmann M, Jonat W, Abel U: Adjuvant chemo-and endocrine therapy alone or in combination in premenopausal patients (GABG trial 1), in Senn HJ, Goldhirsch, A, Gelber RD, Osterwalder B (eds). Adjuvant Therapy of Primary Breast Cancer (Recent Results in Cancer Research). Berlin-Heidelberg-New York, Springer, 1989, pp 118–125.

    Google Scholar 

  29. Ludwig Breast Cancer Study Group. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer. J Clin Oncol 1985;3:1059–1067.

    Google Scholar 

  30. Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491–496.

    Article  Google Scholar 

  31. Maass H, Engel B, Hohmeister H, Lehmann F, Trams G: Estrogen receptors in human breast cancertissue. Am J Obstet Gynecol 1972;113:377–382.

    PubMed  CAS  Google Scholar 

  32. Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G: Efficacy of adjuvant chemotherapy in highrisk node-negative breast cancer. N Engl J Med 1989;320:485–490.

    Article  PubMed  CAS  Google Scholar 

  33. Meakin JW: A randomized trial of adjuvant tamoxifen in postmenopausal women with axillary node-positive breast cancer. Reviews Endocrine-Related Cancer 1985: (Suppl 17):39–41.

    Google Scholar 

  34. Meakin JW, Allt WEC, Beale FA, Brown TC, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, Jenkin RDT, Pringle JF, Reid JG, Rider WD, Hayward JL, Bulbrook RD: Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Ass J 1979;120:1221–1229.

    PubMed  CAS  Google Scholar 

  35. Meakin JW, Allt WEC, Beale FA, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, Jenkin RDT, Pringle JF, Reid JG, Rider WD, Hayward JL, Bulbrook RD: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1983;3 (Suppl 1):45–48.

    Article  Google Scholar 

  36. Mouridsen HT, Rose C, Overgaard M, Dombernowsky P, Panduro J, Thorpe S, Rasmussen BB, Blichert-Toft M, Andersen KW: Adjuvant treatment of postmenopausal patients with high-risk primary breast cancer. Acta Oncologica 1988;27 (Fasc 6a):699–705.

    Article  PubMed  CAS  Google Scholar 

  37. National Institutes of Health, Consensus development conference statement: Treatment of early breast cancer. 18.–21. Juni 1990.

  38. Nevinny HB, Nevinny B, Rosoff B: Prophylactic oophorectomy in breast cancer therapy. A prelimanary report. Am J Surg 1969;117:531–536.

    Article  Google Scholar 

  39. Nissen-Meyer R: The role of prophylatic castration in the therapy of human mammary cancer. Eur J Cancer 1967;3:395–405.

    PubMed  CAS  Google Scholar 

  40. Palshof T, Carstensen B, Mouridsen HT, Dombernowsky P: Adjuvant endocrine therapy in preand postmenopausal women with operable breast cancer. Reviews on Endocrine-Related Cancer 1985;(Suppl 17):43–50.

    Google Scholar 

  41. Ravdin RG, Lewison EF, Slack NH, Dao TI, Gardner B, State D, Fisher B: Results of a clinical trial conceming the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 1970;131:1055–1064.

    PubMed  CAS  Google Scholar 

  42. Ribeiro G, Swindell R: The Christie hospital adjuvant tamoxifen trial—status at 10 years. Br J Cancer 1988;57:601–603.

    PubMed  CAS  Google Scholar 

  43. Rosenberg MF, Uhlmann EM: Prophylactic castration in carcinoma of the breast. Arch Surg 1959;78:376–379.

    CAS  Google Scholar 

  44. Rutqvist LE, Cedermark B, Glas U, Johansson H; Rotstein S, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar M-L: Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990;66:89–96.

    Article  PubMed  CAS  Google Scholar 

  45. Schinzinger A: Über Carcinoma mammae. Zbl Chir 1889;16:55–56.

    Google Scholar 

  46. Siegert A: Kastration und Mammakarzinom. Strahlentherapie 1952;87:62–64.

    PubMed  CAS  Google Scholar 

  47. Smith GV, Smith OW: Carcinoma of the breast. Results, evaluation of x-irradiation, and relation of age and surgical castration to length of survival. Surg Gynecol Obstet 1953;97:508–516.

    PubMed  CAS  Google Scholar 

  48. Taylor GW: Artificial menopause in carcinoma of the breast: N Engl J Med 1934;211:1138–1140.

    Article  Google Scholar 

  49. Tormey DC, Gray R, Gilchrist K, Grage T, Carbone PP, Wolter J, Woll JE, Cummings FJ: Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. Cancer 1990;65:200–206.

    Article  PubMed  CAS  Google Scholar 

  50. Tormey DC, Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 1984;4:297–302.

    Article  PubMed  CAS  Google Scholar 

  51. Treves N: An evaluation of prophylactic castration in the treatment of mammary carcinoma. Cancer 1957;10:393–407.

    Article  PubMed  CAS  Google Scholar 

  52. Wallgren A, Baral E, Carstensen J, Friberg S, Glas U, Hjalmar M-L, Kaigas M, Norkenskjöld B, Skcog L, Theve N-O, Wilking N: Adjuvant “Nolvadex” treatment in postmenopausal breast cancer: the Stockholm experience. Reviews on Endocrine-Related Cancer 1985; (Suppl 17):35–37.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Frauenklinik Hamburg-Eppendorf, Martinistraße 52, D-2000, Hamburg 20

    H. Eidtmann & W. Jonat

Authors
  1. H. Eidtmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Jonat
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eidtmann, H., Jonat, W. Adjuvante hormonelle Therapie beim Mammakarzinom. Acta Chir Austriaca 23, 57–62 (1991). https://doi.org/10.1007/BF02658927

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02658927

Schlüsselwörter

Key-words

Search

Navigation